Background In autosomal dominant polycystic kidney disease (ADPKD), hypertension is
prevalent and cardiovascular events are the main cause of death. Thiazide diuretics are …

Background The TEMPO 3: 4 Trial results suggested that tolvaptan had no effect compared
with placebo on albuminuria in autosomal-dominant polycystic kidney disease (ADPKD) …

Purpose Tolvaptan, a vasopressin V2 receptor antagonist, slows the decline in renal
function in autosomal dominant polycystic kidney disease (ADPKD). However, it increases …

Renal tubular acidosis (RTA) is a hyperchloremic metabolic acidosis characterized by a
normal anion gap and normal (or near normal) glomerular filtration rate in the absence of …

Objective The objective of this meta-analysis was to compare the efficacy and drug safety of
tolvaptan with placebo for autosomal dominant polycystic kidney disease (ADPKD). Methods …

Renal tubular acidosis (RTA) occurs when the kidneys are unable to maintain normal acid−
base homeostasis because of tubular defects in acid excretion or bicarbonate ion …

Background About one in 2000 persons in Europe suffers from autosomal dominant
polycystic kidney disease (ADPKD). The treatment of this disease up to the present has …

Background Hyperuricemia has been implicated in the development and progression of
chronic kidney disease, both in animal experiments and in clinical studies. As a potentially …

Background Currently, the vasopressin V2 receptor antagonist tolvaptan is the only
available treatment for autosomal dominant polycystic kidney disease (ADPKD), but there …

Haematuria has long been considered to be a benign condition associated with glomerular
diseases. However, new evidences suggest that haematuria has a pathogenic role in …